Kwality Pharmaceuticals Enters European Markets with Leuprorelin Acetate Approval in Greece

Kwality Pharmaceuticals Ltd has received approval for Leuprorelin Acetate for injectable suspension as a site variation from Greece. This marks the company's entry into the European markets. Kwality Pharma will supply the first three validation batches in December and start regular supplies from January 2025. This strategic CDMO arrangement is projected to generate around USD 3 million of yearly sales. The company also plans to add remaining strengths of the same in the product portfolio with the same buyer.